Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.
A key role for microRNA-155 in brain inflammation and neurodegeneration makes it both a potential therapeutic target and a biomarker for this progressive disorder.
Haydeh Payami, Ph.D., a leading geneticist recruited to the UAB-Hudson Alpha Center for Genomic Medicine and UAB Personalized Medicine Institute, is exploring the protective power of coffee and nicotine — and the mysteries of the microbiome — in Parkinson’s disease.
A UAB neuroscience student has received a summer fellowship from the Parkinson’s Disease Foundation.
UAB has teamed with the Michael J. Fox Foundation to look for genetic biomarkers for Parkinson’s disease.
Researchers show that high-intensity strength training improves mobility, mood and overall quality of life for Parkinson’s patients.
Gel form of a medication for Parkinson’s disease speeds response time over traditional pills.
A grant will establish the new Bachmann-Strauss Dystonia and Parkinson’s Disease Centers of Excellence at UAB and two other medical centers.
Can smell tests reveal brain changes that are precursors to Parkinson's? Research podcast with David Standaert, M.D., Ph.D.